INSILICO Enters Global Licensing and AI Drug Development Partnership with Eli Lilly

Stock News03-29

INSILICO (03696) has announced an agreement with Eli Lilly and Company for a licensing and drug development collaboration. The partnership will leverage INSILICO's AI-driven drug discovery capabilities to accelerate the identification and development of novel therapies across multiple therapeutic areas. Under the agreement, Lilly receives an exclusive global license to develop, manufacture, and commercialize a novel oral therapy—currently in the preclinical stage—targeting a specific indication with the potential to become a best-in-class treatment. In addition, by combining INSILICO's advanced Pharma.AI platform with Lilly's expertise in research and disease biology, the two companies will also collaborate on multiple drug discovery programs for targets selected by Lilly. According to the terms, INSILICO is eligible to receive an upfront payment of $115 million, with additional payments upon achieving development, regulatory, and commercial milestones, bringing the total potential deal value to approximately $2.75 billion. INSILICO will also receive tiered royalties on future sales.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment